New treatment developments applied to elderly patients with advanced prostate cancer

被引：20
|
作者：
Mukherji, Deborah [1 ]
Pezaro, Carmel J. [2 ]
Shamseddine, Ali [1 ]
De Bono, Johann S. [2 ]
机构：
[1] Amer Univ Beirut, Med Ctr, Dept Hematol Oncol, Beirut 11072020, Lebanon
[2] Royal Marsden NHS Fdn Trust, Prostate Targeted Therapy Grp, Sutton SM25PT, Surrey, England
来源：
CANCER TREATMENT REVIEWS | 2013年 / 39卷 / 06期
关键词：
Castration resistant prostate cancer; CRPC; Elderly; Abiraterone; Cabazitaxel; Sipuleucel-T; Enzalutamide; Alpharadin; Denosumab; I CLINICAL-TRIAL; ABIRATERONE ACETATE; PHASE-I; STEROIDAL INHIBITORS; ANDROGEN-DEPRIVATION; ANTITUMOR-ACTIVITY; POST-DOCETAXEL; SIPULEUCEL-T; CYP17; IMMUNOTHERAPY;
D O I：
10.1016/j.ctrv.2012.12.004
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Prostate cancer is a common disease amongst elderly men. Compared with younger patients, men over the age of 75 are more likely to present with advanced disease and have a greater risk of death from prostate cancer despite higher death rates from competing causes. Treatment options for advanced prostate cancer have improved considerably in the last two years. The immunotherapy sipuleucel-T, the cytotoxic cabazitaxel, the androgen biosynthesis inhibitor abiraterone acetate, the radioisotope radium-223 and the antiandrogen enzalutamide have all been shown to improve survival in randomized phase III studies for patients with metastatic castration-resistant prostate cancer. This review will focus on the clinical data regarding new treatment developments specifically applied to elderly patients with advanced prostate cancer. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码：578 / 583
页数：6
相关论文
共 50 条
12345